Xeris Biopharma Holdings (NASDAQ:XERS) Chairman & CEO Paul Edick joins Natalie Stoberman from the Proactive studios to discuss the latest updates on product line performance.
Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a proven therapy for primary periodic paralysis; and Recorlev for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol and XeriJect, to support long-term product development and commercial success.